ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Oct 30, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Oct 22, 2014
ChemoCentryx to Hold Third Quarter 2014 Financial Results Conference Call on Wednesday, November 5, 2014
Oct 21, 2014
ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study
Oct 20, 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease
View all »Events & Presentations
Nov 5, 2014 at 5:00 PM ET
ChemoCentryx, Inc. Third Quarter 2014 Financial Results Conference Call
^ Return to Top